97 related articles for article (PubMed ID: 3120268)
1. Studies of antituberculosis chemotherapy with an in vitro model of human tuberculosis.
Crowle AJ
Semin Respir Infect; 1986 Dec; 1(4):262-4. PubMed ID: 3120268
[TBL] [Abstract][Full Text] [Related]
2. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.
Hartkoorn RC; Chandler B; Owen A; Ward SA; Bertel Squire S; Back DJ; Khoo SH
Tuberculosis (Edinb); 2007 May; 87(3):248-55. PubMed ID: 17258938
[TBL] [Abstract][Full Text] [Related]
3. [Studies on the effect of antituberculosis agents against tubercle bacilli in the resting state, using streptomycin-dependent strain (18-b). I. Studies in vitro].
Ota Y
Kekkaku; 1971 Aug; 46(8):295-301. PubMed ID: 4328204
[No Abstract] [Full Text] [Related]
4. Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages.
Heifets L; Higgins M; Simon B
Int J Tuberc Lung Dis; 2000 Jun; 4(6):491-5. PubMed ID: 10864178
[TBL] [Abstract][Full Text] [Related]
5. Potential use of nitrate reductase as a biomarker for the identification of active and dormant inhibitors of Mycobacterium tuberculosis in a THP1 infection model.
Sarkar S; Sarkar D
J Biomol Screen; 2012 Aug; 17(7):966-73. PubMed ID: 22573731
[TBL] [Abstract][Full Text] [Related]
6. In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis.
Martins M; Schelz Z; Martins A; Molnar J; Hajös G; Riedl Z; Viveiros M; Yalcin I; Aki-Sener E; Amaral L
Int J Antimicrob Agents; 2007 Mar; 29(3):338-40. PubMed ID: 17239569
[TBL] [Abstract][Full Text] [Related]
7. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
8. Antituberculosis activity of certain antifungal and antihelmintic drugs.
Sun Z; Zhang Y
Tuber Lung Dis; 1999; 79(5):319-20. PubMed ID: 10707260
[TBL] [Abstract][Full Text] [Related]
9. [Testing Mycobacterium tuberculosis for drug sensitivity using different methods].
Skriagina EM; Zalutskaia OM; Roth A; Mauch H; Nikolenko EN
Probl Tuberk; 2001; (5):43-5. PubMed ID: 11588962
[TBL] [Abstract][Full Text] [Related]
10. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
11. Intracellular growth and drug susceptibility of Mycobacterium tuberculosis in macrophages.
Chanwong S; Maneekarn N; Makonkawkeyoon L; Makonkawkeyoon S
Tuberculosis (Edinb); 2007 Mar; 87(2):130-3. PubMed ID: 16860611
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of new quinoxalin 1,4-dioxide derivatives against strains of Mycobacterium tuberculosis and other mycobacteria.
Zanetti S; Sechi LA; Molicotti P; Cannas S; Bua A; Deriu A; Carta A; Paglietti G
Int J Antimicrob Agents; 2005 Feb; 25(2):179-81. PubMed ID: 15664491
[No Abstract] [Full Text] [Related]
13. Rapid, automated, nonradiometric susceptibility testing of Mycobacterium tuberculosis complex to four first-line antituberculous drugs used in standard short-course chemotherapy.
Johansen IS; Thomsen VØ; Marjamäki M; Sosnovskaja A; Lundgren B
Diagn Microbiol Infect Dis; 2004 Oct; 50(2):103-7. PubMed ID: 15474318
[TBL] [Abstract][Full Text] [Related]
14. Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method.
van Klingeren B; Dessens-Kroon M; van der Laan T; Kremer K; van Soolingen D
J Clin Microbiol; 2007 Aug; 45(8):2662-8. PubMed ID: 17537932
[TBL] [Abstract][Full Text] [Related]
15. A whole blood bactericidal assay for tuberculosis.
Wallis RS; Palaci M; Vinhas S; Hise AG; Ribeiro FC; Landen K; Cheon SH; Song HY; Phillips M; Dietze R; Ellner JJ
J Infect Dis; 2001 Apr; 183(8):1300-3. PubMed ID: 11262217
[TBL] [Abstract][Full Text] [Related]
16. Bactericidal activity of 2-nitroimidazole against the active replicating stage of Mycobacterium bovis BCG and Mycobacterium tuberculosis with intracellular efficacy in THP-1 macrophages.
Khan A; Sarkar S; Sarkar D
Int J Antimicrob Agents; 2008 Jul; 32(1):40-5. PubMed ID: 18538548
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of an intracellular pharmacokinetic in vitro infection model as a tool to assess tuberculosis therapy.
Cappelletty DM
Int J Antimicrob Agents; 2007 Feb; 29(2):212-6. PubMed ID: 17204402
[TBL] [Abstract][Full Text] [Related]
18. SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis (XDR-TB).
Martins M; Viveiros M; Ramos J; Couto I; Molnar J; Boeree M; Amaral L
Int J Antimicrob Agents; 2009 May; 33(5):479-82. PubMed ID: 19155160
[TBL] [Abstract][Full Text] [Related]
19. [Studies on the effects of antituberculosis agents against tubercle bacilli in the resting state, using streptomycin-dependent strain (18-b). II. Studies in vivo].
Ota Y
Kekkaku; 1971 Dec; 46(12):493-500. PubMed ID: 5004603
[No Abstract] [Full Text] [Related]
20. Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy.
Kalita A; Verma I; Khuller GK
J Infect Dis; 2004 Oct; 190(8):1476-80. PubMed ID: 15378441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
